The Global Ebola Virus Vaccine Market is expected to grow with a CAGR of 30.9% over the forecast period.
Global Ebola Virus Vaccine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Rising cases of Ebola disease, increasing number of government initiatives for the development of vaccines as well as rising investment in research and development are some of the major factors driving the growth of the Global Ebola Virus Vaccine Market.
Ebola is one the major life-threatening disease in the world which occurs from blood clotting. It is mostly commonly occurred into the African countries. It is known as a hemorrhagic fever virus, due to the clotting problems prime to internal bleeding, as blood outflows from small blood vessels in body. It is caused by an infection with a group of viruses within the genus Ebolavirus. For example; Ebola virus, Sudan virus, Taï Forest virus, Bundibugyo virus, Reston virus, Bombali virus and others. Ebola first appeared in 1976 in two simultaneous outbreaks in Africa.
The Covid-19 outbreak has slightly affected the Ebola virus vaccine market in the year 2020 due to the strict lockdown measures and social distancing norms across the globe. Similarly, manufacturing facilities around the world were shut down during the initial stages of the pandemic. Due to the unbreakable spread and increasing death rate governments are trying to conquer the situation and pharmaceutical companies rushed towards the research and development and production of the coronavirus vaccine. Al this focus on the pandemic has affected the Ebola virus vaccine market growth. Despite this, a number of Ebola vaccines are in clinical trial phases. For example; on November 11th, 2021; The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers.
The global Ebola virus vaccine market is segmented based on type, end-user, and region & country level. Based on type, the global ebola virus vaccine market is classified into, Ebola Virus, Sudan Virus, Taï Forest Virus and Bundibugyo Virus. Based on end-user, global Ebola Virus vaccine is classified into, hospital, ambulatory surgical centers, clinics and others.
Some of the key players for global Ebola virus vaccine are Merck & Co., Inc, NewLink Genetics Corporation, Johnson & Johnson Private Limited, GlaxoSmithKline plc, Novavax, Inc, GeoVax, Mapp Biopharmaceutical, Arbutus Biopharma, Bavarian Nordic, Nanoviricides, Inc., Sarepta Therapeutics, Chimerix, Biocryst Pharmaceuticals, Inc., Hemispherx Biopharma, Inc, Biocomo, Peptineo, Bio-Excel, Geneone Life Sciences, Inc, IMV Inc, Etubics and others.
On November 11th, 2021; The University of Oxford launched phase one of its trials, testing the vaccine in human volunteers. Phase one of the trials will see 26 people aged 18 to 55 receive one dose of the ChAdOx1 biEBOV Ebola vaccine at the university. They will then be monitored over a six-month period, with results expected in the second quarter of 2022.
On December 19th, 2019; The Food and Drug Administration announced that it has approved an Ebola vaccine developed by Merck, making it the first for the deadly disease approved in the United States. The FDA have announced the approval of Ervebo, the first FDA-approved Ebola vaccine. Also known as V920, this vaccine was developed by Merck & Co (NJ, USA) and received positive responses from the European Commission and the WHO in November 2019.
On September 29th, 2017; The U.S. government is investing more than USD 170 million to help two new vaccines against the Ebola virus and two Ebola drugs. The investment includes the purchase of up to 1.13 million courses of vaccine, including a single-dose vaccine from Merck & Co and a two-dose vaccine from Johnson & Johnson.
Rising Cases of Ebola Disease, Growing Number of Government Initiatives for the Development of Vaccines and Increasing Number of Research & Development Activities in This Field are Some of the Major Factors Driving the Market Growth
In the recent year, the world is facing various types of infectious disease spread and one of them is Ebola. Ebola is a disease which transmitted to people from animals and then it spread from human to human via direct contacts. In addition, the increasing infection is major concerning factor around the globe. Ebola has so far only affected African countries, and rare cases across the continent are growing rapidly. But the virus can mutate to spread more easily among people, making it a risk factor for a pandemic. Due to these factors, the demand of Ebola vaccine is growing. For example; according to Centers for Disease Control and Prevention; on March 29th, 2016, the WHO lifted the PHEIC status on West Africa’s Ebola situation. A total of 28,616 cases and 11,310 deaths have been reported from the Ebola virus in Guinea, Liberia and Sierra Leone. The impact of this epidemic on the world and especially on West Africa is significant.
In addition, increasing spread of the Ebola virus outbreak is creating a huge burden on the health department in African countries. The Ebola resulted in the governments of the hardest-hit countries and the World Health Organization declaring a national emergency. The presence of Ebola disease is not limited to one region it slowly occupied other regions. Due to this, governments are trying to prevent the spread and deaths caused by Ebola various countries' governments are taking initiatives to invent vaccines by investing funds in research and development.
Similarly, various pharmaceutical countries are also investing in research and development in this field and some of the vaccines are in the trial phase. For example; supporting the on-going response to the Ebola outbreak in the Democratic Republic of Congo (DRC) in 2019, the FDA and government partners are conducting studies to better understand how Ebola survivors in West Africa are affected and how to treat these patients more effectively. However, stringent rules and regulations and health concerns may hinder the market growth. Despite this, increasing investment in this field may create more opportunities for the further growth of the market.
North America accounted the largest share of the Ebola virus vaccine market due to the increasing number of pharmaceutical companies taking initiative to research and development in Ebola virus vaccine market. For example; National Institute of Allergy and Infectious Diseases have supported the development of a variety of candidates, including the rVSV-ZEBOV vaccine developed by Merck. The candidate has been administered to people at risk of contracting the Ebola virus in the Democratic Republic of the Congo (DRC) and has been tested in NIAID-backed clinical trials in East-West Africa. In addition, the number of pharmaceutical companies working on Ebola vaccine is in pipeline to approval, similarly, FDA approval for a new vaccine is nourishing the North American region. For example; in 2019 FDA approved the treatment for the Ebola virus “Ervebo,” it is the first FDA-approved vaccine for the prevention of Ebola virus disease (EVD), caused by Zaire Ebola virus in individuals 18 years of age and older. And another example; in Guinea the World Health Organization (WHO) is launching a new clinical trial in response and will be deploying the Ebola vaccine regimen developed by the Janssen Pharmaceutical Companies of Johnson & Johnson in collaboration with Bavarian Nordic A/S to frontline and healthcare workers, as well as others at risk of Ebola virus disease in February 2021.
Europe and the Middle East & Africa regions are following the market growth due to the outbreak of the Ebola virus in African countries. For the past few years, African countries are facing Ebola outbreaks and increasing death rates. The government of African countries are taking initiative towards the awareness of Ebola virus and Ebola virus vaccination. In the last 2-3years, Food and Drug Administration approved vaccines for Ebola and due to this, the Ebola vaccine demand is increased in African countries. For example; Johnson & Johnson announced in 2019 that it would provide up to 500,000 vaccine regimens for a new clinical study to make the vaccine available to individuals at some risk of Ebola infection who live in areas close to the outbreak zone, with the goal of helping prevent further geographic spread of the disease.
Middle East and Africa
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2021:||USD XX Million|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD XX Million|
|Tables, Charts & Figures:||175|
|Ebola Vaccine Manufacturers||Merck & Co., Inc, NewLink Genetics Corporation, Johnson & Johnson Private Limited, GlaxoSmithKline plc, Novavax, Inc, GeoVax, Mapp Biopharmaceutical, Arbutus Biopharma, Bavarian Nordic, Nanoviricides, Inc., Sarepta Therapeutics, Chimerix, Biocryst Pharmaceuticals, Inc., Hemispherx Biopharma, Inc, Biocomo, Peptineo, Bio-Excel, Geneone Life Sciences, Inc, IMV Inc, Etubics and others.|
|Segments Covered||By Type, By End-User|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
Kemp House, 152 - 160 City Road, London EC1V 2NX
© Copyright 2022-23 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®